An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist

FEBS Letters

Volumn 588, Issue 24, 2014, Pages 4831-4837

  Liu, Cassie J ^a   Jones, Douglas S ^a   Tsai, Ping Chuan ^a   Venkataramana, Abhishek ^a   Cochran, Jennifer R ^a  

^a Stanford University   (United States)

Author keywords

c MET receptor; Hepatocyte growth factor; Ligand receptor interaction; Protein engineering; Receptor agonist; Tissue regeneration

Indexed keywords

DIMER; MONOMER; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; PEPTIDE FRAGMENT;

ARTICLE; BINDING AFFINITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; AGONISTS; CELL MOTION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STABILITY; TEMPERATURE;

CELL MOVEMENT; CELL PROLIFERATION; HEPATOCYTE GROWTH FACTOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PEPTIDE FRAGMENTS; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE, QUATERNARY; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TEMPERATURE;

EID: 84915745204     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.11.018     Document Type: Article

References (57)

1. T. Nakamura, and S. Mizuno The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine Proc. Jpn. Acad. B 86 2010 588 610 10.2183/pjab.86.588
2. L. Trusolino, A. Bertotti, and P.M. Comoglio MET signalling: principles and functions in development, organ regeneration and cancer Nat. Rev. Mol. Cell Biol. 11 2010 834 848 10.1038/nrm3012
3. E. Gherardi, W. Birchmeier, C. Birchmeier, and G. Vande Woude Targeting MET in cancer: rationale and progress Nat. Rev. Cancer 12 2012 89 103 10.1038/nrc3205
4. K.E. Landgraf, L. Santell, and K.L. Billeci Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling J. Biol. Chem. 285 2010 40362 40372 10.1074/jbc.M110.179721
5. S. Pietronave, G. Forte, and D. Locarno Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis Am. J. Physiol. Heart Circ. Physiol. 298 2010 H1155 H1165 10.1152/ajpheart.01323.2008
6. W.-B. Pyun, W. Hahn, and D.-S. Kim Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia Gene Ther. 17 2010 1442 1452 10.1038/gt.2010.101
7. K.W. Rickert, S.B. Patel, and T.J. Allison Structural basis for selective small molecule kinase inhibition of activated c-Met J. Biol. Chem. 286 2011 11218 11225 10.1074/jbc.M110.204404
8. M. Mazzone, C. Basilico, and S. Cavassa An uncleavable form of pro - scatter factor suppresses tumor growth and dissemination in mice J. Clin. Invest. 114 2004 1418 1432 10.1172/JCI200422235.1418
9. S.A. Greenall, E. Gherardi, and Z. Liu Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET PLoS ONE 7 2012 e34658 10.1371/journal.pone.0034658
10. D. Kirchhofer, M.T. Lipari, and L. Santell Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist Proc. Natl. Acad. Sci. U.S.A. 104 2007 5306 5311 10.1073/pnas.0700184104
11. W.D. Tolbert, J. Daugherty, and C. Gao A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist Proc. Natl. Acad. Sci. U.S.A. 104 2007 14592 14597 10.1073/pnas.0704290104
12. M. Youles, O. Holmes, and M.V. Petoukhov Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist J. Mol. Biol. 377 2008 616 622 10.1016/j.jmb.2008.01.034
13. M. Merchant, X. Ma, and H.R. Maun Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent Proc. Natl. Acad. Sci. U.S.A. 110 2013 E2987 E2996 10.1073/pnas.1302725110
14. Y. Kwon, B.D. Smith, and Y. Zhou Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment Oncogene 1-10 2013 10.1038/onc.2013.539
15. K.E. Landgraf, M. Steffek, and C. Quan An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides Nat. Chem. Biol. 10 2014 567 573 10.1038/nchembio.1533
16. D.P. Bottaro, J.S. Rubin, and D.L. Faletto Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product Science 251 1991 802 804
17. S. Wilke, J. Krausze, and M. Gossen Glycoprotein production for structure analysis with stable, glycosylation mutant CHO cell lines established by fluorescence-activated cell sorting Protein Sci. 19 2010 1264 1271 10.1002/pro.390
18. Y. Shirakawa, Y. Sawa, and Y. Takewa Gene transfection with human hepatocyte growth factor complementary DNA plasmids attenuates cardiac remodeling after acute myocardial infarction in goat hearts implanted with ventricular assist devices J. Thorac. Cardiovasc. Surg. 130 2005 624 632 10.1016/j.jtcvs.2004.02.045
19. G. Hartmann, T. Prospero, and V. Brinkmann Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo Curr. Biol. 8 1998 125 134 10.1016/S0960-9822(98)70059-4
20. R.S. Roy, S. Soni, and R. Harfouche Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis PNAS 107 2010 13608 13613 10.1073/pnas.1006007107/-/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1006007107
21. D. Lietha, D.Y. Chirgadze, and B. Mulloy Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor EMBO J. 20 2001 5543 5555 10.1093/emboj/20.20.5543
22. J. Ross, E. Gherardi, and N. Mallorqui-Fernandez Protein engineered variants of hepatocyte growth factor/scatter factor promote proliferation of primary human hepatocytes and in rodent liver Gastroenterology 142 2012 897 906 10.1053/j.gastro.2011.12.006
23. J.L. Jakubczak, W.J. Larochelle, and G. Merlino NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo Mol. Cell. Biol. 18 1998 1275 1283
24. R.H. Schwall, L.Y. Chang, and P.J. Godowski Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2 J. Cell Biol. 133 1996 709 718 10.1083/jcb.133.3.709
25. O. Holmes, S. Pillozzi, and J.A. Deakin Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains J. Mol. Biol. 367 2007 395 408 10.1016/j.jmb.2006.12.061
26. D.Y. Chirgadze, J.P. Hepple, and H. Zhou Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding Nat. Struct. Biol. 6 1999 72 79 10.1038/4947
27. H. Sakata, S.J. Stahl, and W.G. Taylor Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms: heparan sulfate glycosaminoglycan requirement for met binding and signaling J. Biol. Chem. 272 1997 9457 9463 10.1074/jbc.272.14.9457
28. S.J. Stahl, P.T. Wingfield, and J.D. Kaufman Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli Biochem. J. 326 1997 763 772
29. D.S. Jones, P.-C. Tsai, and J.R. Cochran Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists Proc. Natl. Acad. Sci. U.S.A. 108 2011 13035 13040 10.1073/pnas.1102561108
30. K. Watanabe, D.Y. Chirgadze, and D. Lietha A new crystal form of the NK1 splice variant of HGF/SF demonstrates extensive hinge movement and suggests that the NK1 dimer originates by domain swapping J. Mol. Biol. 319 2002 283 288 10.1016/S0022-2836(02)00199-7
31. M. Sattler, Y.B. Pride, and P. Ma A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase Cancer Res. 63 2003 5462 5469
32. H.-J. Park, Y. Zhang, and S.P. Georgescu Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis Stem Cell Rev. 2 2006 93 102 10.1007/s12015-006-0015-x
33. Z. Yang, M.W. von Ballmoos, and D. Faessler Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced apoptosis of mature endothelial cells Atherosclerosis 211 2010 103 109 10.1016/j.atherosclerosis.2010.02.022
34. M. Miya, A. Maeshima, and K. Mishima Enhancement of in vitro human tubulogenesis by endothelial cell-derived factors: implications for in vivo tubular regeneration after injury Am. J. Physiol. Renal Physiol. 301 2011 387 395 10.1152/ajprenal.00619.2010
35. D.M. Ornitz, A. Yayon, and J.G. Flanagan Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells Mol. Cell. Biol. 12 1992 240 247 10.1128/MCB.12.1.240
36. F. Bussolino, M.F. Di Renzo, and M. Ziche Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth J. Cell Biol. 119 1992 629 641
37. O. Higuchi, K. Mizuno, G.F. Vande Woude, and T. Nakamura Expression of c-met proto-oncogene in COS cells induces the signal transducing high-affinity receptor for hepatocyte growth factor FEBS Lett. 301 1992 282 286 10.1016/0014-5793(92)80257-H
38. J.-A. Chen, M. Shi, J.-Q. Li, and C.-N. Qian Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration Hepatol. Int. 4 2010 537 547 10.1007/s12072-010-9192-4
39. U.G.O. Cavallaro, Z. Wu, and A.D.I. Palo FGF-2 stimulates migration of Kaposi's sarcoma-like vascular cells by HGF-dependent relocalization of the urokinase receptor FASEB J. 12 1998 1027 1034
40. A. Marui, A. Kanematsu, and K. Yamahara Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation J. Vasc. Surg. 41 2005 82 90 10.1016/j.jvs.2004.10.029
41. Kringle Pharma, Inc. A Phase I/II Study to Evaluate the Safety and Efficacy of Intrathecal Injection of KP-100IT in Subjects With Acute Spinal Cord Injury. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2014 August 26]. Available from: < http://clinicaltrials.gov/show/NCT02193334 > NLM Identifier: NCT02193334.
42. Kringle Pharma, Inc.; Keio University School of Medicine. A Phase I, Dose-Escalating Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Intrathecal Infusion of KP-100IT through SM-1500 in Subjects with Amyotrophic Lateral Sclerosis (ALS). In: World Health Organization [Internet]. 2014-[cited 2014 August 26]. Available from: < http://apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN-UMIN000007062 > NLM Identifier: JPRN-UMIN000007062.
43. A. Ido, A. Moriuchi, and M. Numata Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety J. Transl. Med. 9 2011 55 10.1186/1479-5876-9-55
44. Kringle Pharma Europe AB. A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of ChronSeal® (5-amino-acid deleted recombinant human Hepatocyte Growth Factor (KP-dHGF)), in Subjects with Venous Leg Ulcers. In: EU Clinical Trials Register [Internet]. 2012-[cited 2014 August 26]. Available from: < https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract-number:2007-002695-34 > Identifier: 2007-002695-34.
45. H. Makino, M. Aoki, and N. Hashiya Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease Arterioscler. Thromb. Vasc. Biol. 32 2012 2503 2509 10.1161/ATVBAHA.111.244632
46. R.J. Powell, P. Goodney, and F.O. Mendelsohn Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial J. Vasc. Surg. 52 2010 1525 1530 10.1016/j.jvs.2010.07.044
47. ViroMed Co., Ltd. dba VM BioPharma. Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014-[cited 2014 August 26]. Available from: < http://clinicaltrials.gov/show/NCT02039401 > NLM Identifier: NCT02039401.
48. Angion Biomedica Corp; National Heart, Lung and Blood Institute. Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012-[cited 2014 August 26]. Available from: < http://clinicaltrials.gov/ct2/show/NCT01539590?term=NCT01539590&rank=1 > NLM Identifier: NCT01539590.
49. E. Gherardi, S. Sandin, and M.V. Petoukhov Structural basis of hepatocyte growth factor/scatter factor and MET signalling PNAS 103 2006 4046 4051 10.1073/pnas.0509040103
50. W.D. Tolbert, J. Daugherty-Holtrop, and E. Gherardi Structural basis for agonism and antagonism of hepatocyte growth factor Proc. Natl. Acad. Sci. U.S.A. 107 2010 13264 13269 10.1073/pnas.1005183107
51. J.A. Deakin, B.S. Blaum, and J.T. Gallagher The binding properties of minimal oligosaccharides reveal a common heparan sulfate/dermatan sulfate-binding site in hepatocyte growth factor/scatter factor that can accommodate a wide variety of sulfation patterns J. Biol. Chem. 284 2009 6311 6321 10.1074/jbc.M807671200
52. L. Bai, D.P. Lennon, and A.I. Caplan Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models Nat. Neurosci. 15 2012 862 870 10.1038/nn.3109
53. J.C. Alvarez-Perez, S. Ernst, and C. Demirci Hepatocyte growth factor/c-met signaling is required for β-cell regeneration Diabetes 63 2014 216 223 10.2337/db13-0333
54. H. McKinnon, E. Gherardi, M. Reidy, and D. Bowyer Hepatocyte growth factor/scatter factor and MET are involved in arterial repair and atherogenesis Am. J. Pathol. 168 2006 340 348 10.2353/ajpath.2006.050379
55. R.A. Hortensius, and B.A.C. Harley The use of bioinspired alterations in the glycosaminoglycan content of collagen-GAG scaffolds to regulate cell activity Biomaterials 34 2013 7645 7652 10.1016/j.biomaterials.2013.06.056
56. S.B. Seif-Naraghi, D. Horn, P.J. Schup-Magoffin, and K.L. Christman Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor Acta Biomater. 8 2012 3695 3703 10.1016/j.actbio.2012.06.030
57. M.M. Martino, P.S. Briquez, and A. Ranga Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix Proc. Natl. Acad. Sci. U.S.A. 110 2013 4563 4568 10.1073/pnas.1221602110